Introduction {#s1}
============

Breast cancer is the most common malignancy of women in China and worldwide ([@B1], [@B2]). The variable prognosis of breast cancer, as a heterogeneous tumor, is influenced by different genomic subtypes. Although substantial effort has been dedicated and tremendous advances have been made toward early detection and improvements in systemic therapy, the 5-year relative survival rate remains low ([@B3]). Therefore, patient stratification and individualized precision therapy strategy are needed.

Currently, well-recognized tumor-related histopathologic classification factors including, tumor size, stage, histological type and grade, lymph node status, hormone receptor (HR) status, and human epidermal growth factor receptor 2 (HER2) status are used to predict survival ([@B4]). However, they are usually available for assessment until postoperatively. To determine more reliable and easily obtained prognostic markers, numerous preoperative markers have been comprehensively evaluated in several studies ([@B5], [@B6]). Thus, far, there are few well-recognized preoperative biomarkers that have an independent prognostic value.

The cancer inflammation and the essential immune system role in cancer surveillance and elimination are valuable hallmarks of cancer ([@B7], [@B8]). Systemic inflammatory responses are involved at the molecular level in cancer formation and progression including DNA damage, tumor invasion, angiogenesis promotion, and migration ([@B9]--[@B12]). Furthermore, studies have confirmed that circulating lymphocytes are a potential indicator of the patient\'s inflammatory status ([@B13]). Studies examining the prognostic effects of inflammatory biomarkers in breast cancer have resulted in great improvements in recent years. C-reactive protein, lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and the prognostic nutritional index have been confirmed as potential independent prognostic factors in breast cancer ([@B5], [@B6], [@B14], [@B15]). However, the prognostic value of the systemic immune-inflammation index (SII), combining lymphocyte, platelet, and neutrophil counts, has never been verified in breast cancer. Therefore, this study was aimed at determining the prognostic value of SII in breast cancer.

Patients and Methods {#s2}
====================

Patients
--------

We retrospectively identified patients who underwent surgery for breast cancer from December 2010 to January 2012 at Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China. Histopathological and clinical examinations data were obtained for all patients. The exclusion criteria were as follows: (1) male breast carcinoma; (2) ductal carcinoma *in situ* or distant metastasis; (3) treatment with neoadjuvant chemotherapy or radiotherapy; (4) acute and/or chronic inflammatory, hematologic, or autoimmune diseases; (5) use of immunosuppressive or anti-inflammatory medicines; and (6) loss of complete laboratory data. Tumor staging was based on the 7th edition of the AJCC TNM staging system for breast cancer. The expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 was scored based on the CAP/ASCO guidelines ([@B16], [@B17]). Systematic treatment and radiotherapy were based on National Comprehensive Cancer Network guidelines. Most of them received systematic therapy as adjuvant chemotherapy, endocrine treatment, or Trastuzumab for human epidermal growth factor receptor-2 (Her-2)-positive tumor. Radiotherapy of the chest wall and regional nodes was applied with a dose prescription of 50 Gy in 25 fractions. Patients receiving breast conserving surgery underwent RT of the whole breast up to a median dose of 50 Gy (range, 48--50 Gy) with 1.8--2 Gy/fraction. The median dose of the tumor bed boost was 10 Gy (range, 10--16 Gy).

Data Collection and Definition
------------------------------

The primary preoperative laboratory data from within 3 days of the time of surgery and clinicopathological data were collected from the patients\' medical records. SII was determined using the following formula: SII = P × N/L, where P, N, and L represent the platelet (10^9^/L), neutrophil (10^9^/L) and lymphocyte (10^9^/L) counts, respectively.

Follow-Up
---------

The patients were followed up carefully by conducting an outpatient examination or a telephonic interview. Overall survival (OS), recurrence-free survival (RFS), distant metastasis-free survival (DMFS) were defined as the time from the date of diagnosis to the date of death/first event (recurrence, distant metastasis) or last follow-up.

Statistical Analysis
--------------------

Statistical analyses were performed using the SPSS 23.0 (SPSS, Inc., Chicago, IL) and GraphPad Prism 6.0 software (GraphPad, La Jolla, CA). The best cut-off value of SII was calculated by receiver operating characteristic (ROC) curve analysis use the highest Youden\'s index for predicting survival status. Propensity score matching of 1:3 scheme with a caliper width equal to 0.2 was applied to develop comparable cohorts of patients with low SII value and high SII value. Covariates for matching included age, histological type, T stage, N stage, clinical stage, ER, PR, HER2, and KI67. Association between categorical variables was analyzed using the Chi-square or Fisher exact test. Continuous variables were compared using Mann-Whitney test. The relation between NLR, PLR, and SII was examined with linear regression. Survival curves were calculated using the Kaplan-Meier method and compared via the log-rank test. Simple and multivariate regression analyses were performed using the Cox proportional hazards model and multivariate regression analyses model for variables with *P* \< 0.10 in the univariate analysis. Two-sided *P* \< 0.05 were considered statistically significant.

Results {#s3}
=======

Patient Characteristics
-----------------------

The baseline characteristics of the 1,026 patients included in this study are shown in [Table 1](#T1){ref-type="table"}. Clinical stage I, II, and III disease was noted in 238 (23.2%), 541 (52.7%), and 247 (24.1%) patients, respectively. The median patient age was 47 years (range 22--87 years), and the median follow-up period was 68.5 months (range 0.9--87.5 months). The median OS was 65.8 months, while the 5-year OS rate was 91.5%. During the final follow-up, 101 (9.8%) patients died and 925 (90.2%) were still alive. Patients were stratified by the best cut-off SII value of 601.7 (low, \<601.7; high, \>601.7) and 782 patients showed low SII values whereas 244 patients had high SII values. We analyzed the association between SII and pre-surgical inflammations of NLR and PLR, and there is a linear association between SII and NLR (*P* \< 0.001, *r* = 0.74; [Figure 1A](#F1){ref-type="fig"}) and PLR (*P* \< 0.01, *r* = 0.47; [Figure 1B](#F1){ref-type="fig"}). Then, we further compared the prognostic value of these three and found that SII was better than NLR and PLR (SII AUC = 0.608, NLR AUC = 0.593, PLR = 0.569; [Figure 2](#F2){ref-type="fig"}).

###### 

Clinicopathologic characteristics before and after matching.

  **Characteristic**                                **Primary cohort**   **PSM cohort**                                       
  ------------------------------------------------- -------------------- ---------------- ------- ------------- ------------- -------
  Total                                             782                  244                      656           238           
  Age (years)                                                                             0.003                               0.576
  ≥60                                               132 (12.9%)          22 (2.1%)                71 (7.9%)     22 (24.6%)    
  \<60                                              650 (63.4%)          222 (21.6%)              585 (65.4%)   216 (24.2%)   
  Histological type                                                                       0.159                               0.985
  Invasive ductal carcinoma                         693 (67.5%)          224 (21.8%)              603 (67.4%)   218 (24.4%)   
  Others                                            89 (8.7%)            20 (1.9%)                53 (5.9%)     20 (2.2%)     
  T stage[^\#^](#TN1){ref-type="table-fn"}                                                0.052                               0.897
  1                                                 263 (25.6%)          71 (6.9%)                205 (22.9%)   71 (7.9%)     
  2                                                 449 (43.8%)          141 (13.7%)              386 (43.2%)   141 (15.8%)   
  3                                                 38 (3.7%)            18 (1.8%)                36 (4.0%)     16 (1.8%)     
  4                                                 32 (3.1%)            14 (1.4%)                29 (3.2%)     10 (1.1%)     
  N stage[^\#^](#TN1){ref-type="table-fn"}                                                0.583                               0.965
  0                                                 414 (40.4%)          121 (11.8%)              331 (37.0%)   118 (13.2%)   
  1                                                 195 (19.0%)          68 (6.6%)                168 (18.8%)   65 (7.3%)     
  2                                                 101 (9.8%)           32 (3.1%)                91 (10.2%)    32 (3.6%)     
  3                                                 72 (7.0%)            23 (2.2%)                66 (7.4%)     23 (2.6%)     
  Clinical stage[^\#^](#TN1){ref-type="table-fn"}                                         0.091                               0.925
  I                                                 190 (18.5%)          48 (4.7%)                140 (15.7%)   48 (5.4%)     
  II                                                411 (40.1%)          130 (12.7%)              351 (39.3%)   130 (14.5%)   
  III                                               181 (17.6%)          66 (6.4%)                165 (18.5%)   60 (6.7%)     
  ER                                                                                      0.838                               0.714
  Negative                                          220 (21.4%)          67 (6.5%)                172 (19.2%)   66 (7.4%)     
  Positive                                          562 (54.8%)          177 (17.3%)              484 (54.1%)   172 (19.2%)   
  PR                                                                                      0.319                               0.794
  Negative                                          287 (28.0%)          81 (7.9%)                223 (24.9%)   78 (8.7%)     
  Positive                                          495 (48.2%)          163 (15.9%)              433 (48.4%)   160 (17.9%)   
  HER2                                                                                                                        0.555
  Negative                                          536 (52.2%)          165 (16.1%)      0.788   460 (51.5%)   162 (18.1%)   
  Positive                                          246 (24.0%)          79 (7.7%)                196 (21.9%)   76 (8.5%)     
  Ki67                                                                                    0.934                               0.641
  Negative                                          249 (24.3%)          77 (7.5%)                212 (23.7%)   73 (8.2%)     
  Positive                                          533 (51.9%)          167 (16.3%)              444 (49.7%)   165 (18.5%)   
  Molecular subtype                                                                       0.606                               0.142
  Luminal A                                         189 (18.4%)          55 (5.4%)                163 (18.2%)   54 (6.0%)     
  Luminal B/HER2--                                  272 (26.5%)          88 (8.6%)                238 (26.6%)   87 (7.8%)     
  Luminal B/HER2+                                   189 (18.4%)          54 (5.3%)                159 (17.8%)   51 (5.7%)     
  HER2 enriched                                     57 (5.6%)            25 (2.4%)                37 (4.1%)     25 (2.8%)     
  Triple negative                                   75 (7.3%)            22 (2.1%)                59 (6.6%)     21 (2.3%)     

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; PSM, propensity score matching; SII, systemic immune-inflammation index.

*According to the 7th edition of the UICC/AJCC staging system*.

![Linear regression association between SII and NLR, PLR. Linear regression association curves for: **(A)** SII and NLR; **(B)** SII and PLR.](fonc-10-00580-g0001){#F1}

![Receiver operating characteristic (ROC) curve analysis of SII and NLR, PLR.](fonc-10-00580-g0002){#F2}

The characteristics of two groups were similar, except for the age (*P* = 0.003) and T stage (*P* = 0.052). Therefore, we established a new cohort using propensity score matching (PSM) to avoid potentially confounding the findings. After PSM, 894 patients were identified, and the clinical characteristics among the two groups were well-balanced (all *P* \> 0.05; [Table 1](#T1){ref-type="table"}).

Prognosis Value of SII
----------------------

The 5-year OS rate for the entire cohort was 89.9%, and in the primary cohort, the corresponding values for patients in high SII group was significantly shorter than those in low SII group (85.6%, and 91.3%, respectively, *P* = 0.016, [Figure 3A](#F3){ref-type="fig"}). The 5-year RFS rate for the entire cohort was 96.3%, and the corresponding values was comparable between two groups (95.8 and 96.4%, respectively; *P* = 0.684, [Figure 3B](#F3){ref-type="fig"}). The 5-years DMFS rate for the entire cohort was 88.9%, and this corresponding values was significantly shorter in the high SII group (83.5%) than in the low SII group (90.6%; *P* = 0.007; [Figure 3C](#F3){ref-type="fig"}). Then, we reanalyzed in the PSM cohort and revealed similar differences in the prognosis of the OS (*P* = 0.047) ([Figure 3D](#F3){ref-type="fig"}), RFS (*P* = 0.838; [Figure 3E](#F3){ref-type="fig"}), and DMFS (*P* = 0.018; [Figure 3F](#F3){ref-type="fig"}).

![Kaplan Meier survival curves for overall survival (OS), recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in primary cohort and propensity score matching (PSM) cohort. Kaplan-Meier curves for: **(A)** overall survival in primary cohort; **(B)** overall survival in PSM cohort; **(C)** recurrence-free survival in primary cohort; **(D)** recurrence-free survival in PSM cohort; **(E)** distant metastasis-free survival in primary cohort; **(F)** distant metastasis-free survival in PSM cohort.](fonc-10-00580-g0003){#F3}

Simple and Multivariate Cox Regression Analysis for OS and DMFS
---------------------------------------------------------------

Simple Cox regression analysis in the primary cohort revealed that histological type, T stage, N stage, PR, HER2, Ki67, molecular subtype, and SII all showed significant associations with OS; and histological type, T stage, N stage, and SII all showed significant associations with DMFS. Multivariate survival analysis revealed that SII can independently predict OS (*P* = 0.019; [Table 2](#T2){ref-type="table"}) and DMFS (*P* = 0.008; [Table 3](#T3){ref-type="table"}). Similar results were demonstrated in the PSM cohort ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

###### 

Univariate and multivariate analyses of overall survival.

  **Characteristic**                         **Primary cohort**                                                 **PSM cohort**                                                                                                                                                
  ------------------------------------------ ----------------------- ------------------------------------------ ----------------------- ------------------------------------------ ----------------------- ------------------------------------------ ----------------------- ------------------------------------------
  Age (years)                                1.140 (0.677--1.920)    0.621                                                                                                         1.414 (0.787--2.541)    0.247                                                              
  Histological type                          6.011 (1.482--24.371)   0.012[^\*^](#TN2){ref-type="table-fn"}     3.522 (0.861--14.409)   0.080                                      8.392 (1.170--60.213)   0.034[^\*^](#TN2){ref-type="table-fn"}     5.294 (0.734--38.202)   0.098
  T stage[^\#^](#TN3){ref-type="table-fn"}   2.068 (1.668--2.564)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.204 (0.936--1.550)    0.148                                      2.107 (1.676--2.649)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.197 (0.916--1.563)    0.187
  N stage[^\#^](#TN3){ref-type="table-fn"}   2.508 (2.108--2.984)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   2.373 (1.947--2.892)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   2.528 (2.103--3.039)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   2.398 (1.947--2.954)    \<0.001[^\*^](#TN2){ref-type="table-fn"}
  ER                                         0.665 (0.443--1.000)    0.050                                      0.791 (0.447--1.399)    0.421                                      0.658 (0.429--1.009)    0.055                                      0.789 (0.434--1.435)    0.438
  PR                                         0.493 (0.333--0.728)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   0.642 (0.397--1.040)    0.072                                      0.462 (0.307--0.693)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   0.599 (0.365--0.984)    0.043[^\*^](#TN2){ref-type="table-fn"}
  HER2                                       1.622 (1.092--2.409)    0.017[^\*^](#TN2){ref-type="table-fn"}     0.883 (0.566--1.376)    0.582                                      1.594 (1.053--2.415)    0.028[^\*^](#TN2){ref-type="table-fn"}     0.842 (0.526--1.347)    0.473
  Ki67                                       2.403 (1.427--4.047)    0.001[^\*^](#TN2){ref-type="table-fn"}     1.688 (0.964--2.958)    0.067                                      2.351 (1.372--4.028)    0.002[^\*^](#TN2){ref-type="table-fn"}     1.720 (0.962--3.076)    0.067
  Molecular subtype                          1.337 (1.152--1.553)    \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.106 (0.834--1.468)    0.484                                      1.341 (1.147--1.68)     \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.065 (0.793--1.430)    0.677
  SII                                        1.651 (1.093--2.495)    0.017[^\*^](#TN2){ref-type="table-fn"}     1.646 (1.085--2.496)    0.019[^\*^](#TN2){ref-type="table-fn"}     1.534 (1.003--2.346)    0.048[^\*^](#TN2){ref-type="table-fn"}     1.611 (1.049--2.474)    0.030[^\*^](#TN2){ref-type="table-fn"}

A Cox proportional hazards model was used to conduct multivariate analyses. All variables were transformed into categorical variables. HRs were calculated for age (≥60 y vs. \<60 y); histological type (invasive ductal carcinoma vs. others); T stage (T3-4 vs. T1-2); N stage (N2-3 vs. N0-1); ER (negative vs. positive); PR (negative vs. positive); HER2 (negative vs. positive); Ki67 (negative vs. positive); molecular subtype (others vs. luminal) and SII (high vs. low). We selected variables using the backward stepwise approach. The P-value threshold was 0.10 (P ≥ 0.10) for the removal of insignificant variables from the model.

P \< 0.05: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; PSM, propensity score matching; SII, systemic immune-inflammation index.

*According to the 7th edition of the UICC/AJCC staging system*.

###### 

Univariate and multivariate analyses of distant metastasis-free survival.

  **Characteristic**                         **Primary cohort**                                                **PSM cohort**                                                                                                                                               
  ------------------------------------------ ---------------------- ------------------------------------------ ---------------------- ------------------------------------------ ----------------------- ------------------------------------------ ----------------------- ------------------------------------------
  Age (years)                                0.697 (0.382--1.269)   0.237                                                                                                        0.779 (0.378--1.605)    0.498                                                              
  Histological type                          3.337 (1.229--9.058)   0.018[^\*^](#TN4){ref-type="table-fn"}     2.485 (0.913--6.765)   0.075                                      4.658 (1.148--18.892)   0.031[^\*^](#TN4){ref-type="table-fn"}     3.429 (0.841--13.969)   0.086
  T stage[^\#^](#TN5){ref-type="table-fn"}   1.788 (1.436--2.227)   \<0.001[^\*^](#TN4){ref-type="table-fn"}   1.197 (0.935--1.532)   0.154                                      1.817 (1.435--2.300)    \<0.001[^\*^](#TN4){ref-type="table-fn"}   1.242 (0.953--1.620)    0.109
  N stage[^\#^](#TN5){ref-type="table-fn"}   2.014 (1.713--2.368)   \<0.001[^\*^](#TN4){ref-type="table-fn"}   1.875 (1.565--2.246)   \<0.001[^\*^](#TN4){ref-type="table-fn"}   1.945 (1.639--2.308)    \<0.001[^\*^](#TN4){ref-type="table-fn"}   1.788 (1.477--2.165)    \<0.001[^\*^](#TN4){ref-type="table-fn"}
  ER                                         0.990 (0.650--1.507)   0.962                                                                                                        0.990 (0.632--1.549)    0.964                                                              
  PR                                         0.824 (0.560--1.212)   0.324                                                                                                        0.780 (0.519--1.173)    0.233                                                              
  HER2                                       1.412 (0.958--2.080)   0.081                                      1.120 (0.756--1.659)   0.571                                      1.482 (0.986--2.228)    0.058                                      1.098 (0.723--1.666)    0.661
  Ki67                                       1.431 (0.931--2.199)   0.102                                                                                                        1.554 (0.981--2.461)    0.060                                      1.329 (0.835--2.115)    0.230
  Molecular subtype                          1.002 (0.856--1.174)   0.976                                                                                                        1.031 (0.873--1.217)    0.722                                                              
  SII                                        1.721 (1.157--2.559)   0.007[^\*^](#TN4){ref-type="table-fn"}     1.720 (1.156--2.561)   0.008[^\*^](#TN4){ref-type="table-fn"}     1.635 (1.085--2.463)    0.019[^\*^](#TN4){ref-type="table-fn"}     1.727 (1.144--2.607)    0.009[^\*^](#TN4){ref-type="table-fn"}

A Cox proportional hazards model was used to conduct multivariate analyses. All variables were transformed into categorical variables. HRs were calculated for age (≥60 y vs. \<60 y); histological type (invasive ductal carcinoma vs. others); T stage (T3-4 vs. T1-2); N stage (N2-3 vs. N0-1); ER (negative vs. positive); PR (negative vs. positive); HER2 (negative vs. positive); Ki67 (negative vs. positive); molecular subtype (others vs. luminal) and SII (high vs. low). We selected variables using the backward stepwise approach. The P-value threshold was 0.10 (P ≥ 0.10) for the removal of insignificant variables from the model.

P \< 0.05: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; PSM, propensity score matching; SII, systemic immune-inflammation index.

*According to the 7th edition of the UICC/AJCC staging system*.

Discussion {#s4}
==========

In recent years, many studies have investigated SII in various cancers. Thus, far, there is no study explored the prognostic significance of SII in breast cancer. To our knowledge, this is the first study to date of patients with operable breast cancer, and our results demonstrated that the SII value was an independent marker of survival and may better than NLR and PLR in breast cancer patients.

Recent studies have shown that the systemic inflammatory response can induce malignant tumor behavior and lead to shorter survival durations in patients with malignant solid tumors, and can also predict the prognosis of cancer ([@B18]--[@B21]). SII as a novel systemic immune-inflammation index, that represents the overall inflammatory, and immune status of the patient has proven to be a meaningful preoperative biomarker in various tumors ([@B18], [@B20]--[@B22]). Hu et al. found that in hepatocellular carcinoma SII was associated with circulating tumor cell levels and local recurrence ([@B21]), while Wang et al. noted that SII was associated with age, tumor invasion, local lymph node metastasis, and distant metastasis in gastric cancer ([@B18]). Similar results were also obtained for small cell lung cancer and cancer ([@B22]). However, the prognostic value of SII in breast cancer remains unclear.

Many studies have reported that preoperative inflammation indexes are effective biomarkers in predicting the prognosis in breast cancer ([@B5], [@B6]). Bárbara et al. found that the PLR and NLR were related to clinical outcomes in breast cancer patients ([@B5]). Hideya et al. revealed that the PLR, NLR, and LMR all significantly predict survival in breast cancer and that the prognostic efficiency of the PLR was better than those of the NLR and LMR ([@B14]). The present study also demonstrated that SII can independently predict survival in patients with breast cancer. As a more convenient, more accessible, lower cost, non-invasive prognostic indicator, SII can serve as a supplement to TNM staging and a prognostic predictor for breast cancer patients.

The mechanisms underlying the prognostic significance of SII for the OS in breast cancer remain unclear, and the physiopathologic role of platelets, neutrophils, and lymphocytes might explain this to some extent. By activating the NF-κB and TGF-β/Smad pathways synchronously, platelet-derived TGF-β and direct platelet-tumor cell contacts can induce mesenchymal-like transition and promote metastasis in cancer cells ([@B23], [@B24]). Neutrophils can help cancer cells escape immune surveillance by promoting cancer cell invasion, proliferation, and metastasis ([@B25], [@B26]). Lymphocytes affect tumor growth by secreting cytokines and inducing cytotoxic cell death while inhibiting the proliferation and migration of cancer cells ([@B27]). These existing mechanisms suggest that a higher SII essentially implies a stronger inflammatory response, but a weaker immune defense in cancer patients, resulting in a lower survival rate. SII, which comprehensively reflects the immune, and inflammatory status of the host ([@B21]), promises to be a useful predictor of cancer prognosis in clinical practice. Our research firmly supports this hypothesis. Moreover, further studies need to be conducted to identify the novel mechanisms in the future.

The findings of this study may help clinicians gain a better understanding of the relationship between immunization, inflammation, and cancer. These results may also provide clinicians with a guideline to develop appropriate therapeutic regimens for individualized precision therapy in breast cancer patients. Breast cancer patients showing high preoperative SII values should receive complementary immunotherapy and anti-inflammatory agents like the active anti-inflammatory agent in Thymus vulgaris, Herceptin, and aspirin, which should be administered immediately after surgery.

There are several limitations of this study. Firstly, as a retrospective study with a relatively small sample size obtained at a single center, the conclusions drawn from the current study may be biased and we are actively seeking cooperation from other centers to verify the results. Secondly, although SII is an independent predictor of breast cancer prognosis, its sensitivity, and specificity are not very high, indicating that further prospective studies are required to determine the appropriate cut-off value. Thirdly, the fact that we have collected some survival information over the phone may have introduced information bias. Finally, different surgical procedures may affect inflammatory indicators and inflammatory indicators may also change before and after surgery ([@B28]--[@B30]). In view of the limitation of existing data (only 185 patients underwent breast-conserving surgery), we will further study the influence of different surgical procedures and changes in preoperative and postoperative inflammatory indicators on the prognosis in subsequent studies.

Conclusions {#s5}
===========

In summary, the current results confirm that SII is a prospective biomarker to predict the clinical outcome in breast cancer. High SII values indicate a higher risk of mortality and distant metastasis among breast cancer patients.
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